The USAN Council (USANC) has selected the name altiratinib for DCC-2701. Deciphera has initiated a clinical Phase 1A trial on altiratinib (DCC-2701) to establish its safety and tolerability in patients with solid tumors (Press release Deciphera Pharmaceuticals, MAY 9, 2014, View Source [SID:1234500713]). Altiratinib potently inhibits MET, TIE-2 VEGFR2 and TRK kinases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!